Compare Impinj Inc (PI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Impinj Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Impinj Inc trades at $186.42 (market cap $5.60B), while State Street SPDR S&P Biotech ETF trades at $153.1 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Impinj Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Impinj Inc for 22 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| PI | XBI | |
|---|---|---|
Market Cap | $5.60B | $10.11B |
Volume | 9,929 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $241.91 | $169.55 |
52-Week Low | $91.34 | $104.99 |
Typical Hold Time | 22 Days | 37 Days |
Enterprise Value | $5.73B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Impinj (PI) trades at $186.53, down 2.36% with a bullish technical outlook despite negative profitability metrics. The stock shows strong analyst support with 16 buy ratings and a $178.83 consensus target. Recent Q2 2026 earnings beat expectations with $0.86 EPS, while revenue growth continues but net margins remain negative at -7.26%. The company maintains solid cash flow from operations of $58.75M in 2025.
Investment outlook balances growth potential against profitability challenges. The RAIN RFID technology market offers expansion opportunities, but elevated valuations (P/S 14.83) and negative ROE (-12.87%) present risks. Near-term catalysts include Q3 2026 results, while competitive pressures and execution risks require monitoring for sustained shareholder value creation.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
